326 related articles for article (PubMed ID: 32065106)
41. Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
Vögerl K; Ong N; Senger J; Herp D; Schmidtkunz K; Marek M; Müller M; Bartel K; Shaik TB; Porter NJ; Robaa D; Christianson DW; Romier C; Sippl W; Jung M; Bracher F
J Med Chem; 2019 Feb; 62(3):1138-1166. PubMed ID: 30645113
[TBL] [Abstract][Full Text] [Related]
42. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
Liu Z; Cai Y; Yang Y; Li A; Bi R; Wang L; Shen X; Wang W; Jia Y; Yu B; Cao B; Cui W; Wei P; Zhou X
J Pathol; 2018 Oct; 246(2):141-153. PubMed ID: 29876933
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010-2020).
Li Y; Sang S; Ren W; Pei Y; Bian Y; Chen Y; Sun H
Eur J Med Chem; 2021 Dec; 226():113874. PubMed ID: 34619465
[TBL] [Abstract][Full Text] [Related]
44. Synthesis and biological evaluation of selective histone deacetylase 6 inhibitors as multifunctional agents against Alzheimer's disease.
Wang XX; Xie F; Jia CC; Yan N; Zeng YL; Wu JD; Liu ZP
Eur J Med Chem; 2021 Dec; 225():113821. PubMed ID: 34517222
[TBL] [Abstract][Full Text] [Related]
45. Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
Liang T; Xue J; Yao Z; Ye Y; Yang X; Hou X; Fang H
Eur J Med Chem; 2021 Oct; 221():113526. PubMed ID: 33992929
[TBL] [Abstract][Full Text] [Related]
46. Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype.
Olaoye OO; Watson PR; Nawar N; Geletu M; Sedighi A; Bukhari S; Raouf YS; Manaswiyoungkul P; Erdogan F; Abdeldayem A; Cabral AD; Hassan MM; Toutah K; Shouksmith AE; Gawel JM; Israelian J; Radu TB; Kachhiyapatel N; de Araujo ED; Christianson DW; Gunning PT
J Med Chem; 2021 Mar; 64(5):2691-2704. PubMed ID: 33576627
[TBL] [Abstract][Full Text] [Related]
47. Involvement of HDAC6 in ischaemia and reperfusion-induced rat retinal injury.
Yuan H; Li H; Yu P; Fan Q; Zhang X; Huang W; Shen J; Cui Y; Zhou W
BMC Ophthalmol; 2018 Nov; 18(1):300. PubMed ID: 30453928
[TBL] [Abstract][Full Text] [Related]
48. Groebke Blackburn Bienaymé-mediated multi-component synthesis of selective HDAC6 inhibitors with anti-inflammatory properties.
Kraft FB; Enns J; Honin I; Engelhardt J; Schöler A; Smith ST; Meiler J; Schäker-Hübner L; Weindl G; Hansen FK
Bioorg Chem; 2024 Feb; 143():107072. PubMed ID: 38185013
[TBL] [Abstract][Full Text] [Related]
49. Do biological activities of selective histone deacetylase 6 (HDAC6) inhibitors rely on the modification of cap group?
Liu X; Wang S; Shi X; Lu M; Wang C; Li X; Zhang Y; Jia Q; Liu H
J Mol Recognit; 2022 Dec; 35(12):e2988. PubMed ID: 36054561
[TBL] [Abstract][Full Text] [Related]
50. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
[TBL] [Abstract][Full Text] [Related]
51. Comprehensive Mechanistic View of the Hydrolysis of Oxadiazole-Based Inhibitors by Histone Deacetylase 6 (HDAC6).
Motlová L; Šnajdr I; Kutil Z; Andris E; Ptáček J; Novotná A; Nováková Z; Havlínová B; Tueckmantel W; Dráberová H; Majer P; Schutkowski M; Kozikowski A; Rulíšek L; Bařinka C
ACS Chem Biol; 2023 Jul; 18(7):1594-1610. PubMed ID: 37392419
[TBL] [Abstract][Full Text] [Related]
52. A Rational Approach for the Identification of Non-Hydroxamate HDAC6-Selective Inhibitors.
Goracci L; Deschamps N; Randazzo GM; Petit C; Dos Santos Passos C; Carrupt PA; Simões-Pires C; Nurisso A
Sci Rep; 2016 Jul; 6():29086. PubMed ID: 27404291
[TBL] [Abstract][Full Text] [Related]
53. HDAC6 as privileged target in drug discovery: A perspective.
Pulya S; Amin SA; Adhikari N; Biswas S; Jha T; Ghosh B
Pharmacol Res; 2021 Jan; 163():105274. PubMed ID: 33171304
[TBL] [Abstract][Full Text] [Related]
54. Isoform-selective HDAC1/6/8 inhibitors with an imidazo-ketopiperazine cap containing stereochemical diversity.
Lecointre B; Narozny R; Borrello MT; Senger J; Chakrabarti A; Jung M; Marek M; Romier C; Melesina J; Sippl W; Bischoff L; Ganesan A
Philos Trans R Soc Lond B Biol Sci; 2018 Jun; 373(1748):. PubMed ID: 29685969
[TBL] [Abstract][Full Text] [Related]
55. Histone deacetylase 6 in cancer.
Li T; Zhang C; Hassan S; Liu X; Song F; Chen K; Zhang W; Yang J
J Hematol Oncol; 2018 Sep; 11(1):111. PubMed ID: 30176876
[TBL] [Abstract][Full Text] [Related]
56. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.
Beyer M; Kiweler N; Mahboobi S; Krämer OH
Methods Mol Biol; 2017; 1510():355-364. PubMed ID: 27761834
[TBL] [Abstract][Full Text] [Related]
57. A Computational Approach to Investigate the HDAC6 and HDAC10 Binding Propensity of Psidium guajava-derived Compounds as Potential Anticancer Agents.
Adewole KE; Ishola AA
Curr Drug Discov Technol; 2021; 18(3):423-436. PubMed ID: 32357815
[TBL] [Abstract][Full Text] [Related]
58. Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors.
Porter NJ; Mahendran A; Breslow R; Christianson DW
Proc Natl Acad Sci U S A; 2017 Dec; 114(51):13459-13464. PubMed ID: 29203661
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of HDAC6 activity in kidney diseases: a new perspective.
Ke B; Chen Y; Tu W; Ye T; Fang X; Yang L
Mol Med; 2018 Jun; 24(1):33. PubMed ID: 30134806
[TBL] [Abstract][Full Text] [Related]
60. Enantioselective synthesis and biological investigation of tetrahydro-β-carboline-based HDAC6 inhibitors with improved solubility.
Grünstein E; Sellmer A; Mahboobi S
Arch Pharm (Weinheim); 2019 Jun; 352(6):e1900026. PubMed ID: 31056792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
